Eisai | GenomeWeb

Eisai

Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

Under the terms of the deal, Oncodesign will conduct in vivo pharmacology studies, while Eisai will do gene expression analysis.

Given its interest in developing treatments for Alzheimer's disease (AD), Japanese drugmaker Eisai is exploring the potential of plasma-based microRNAs to serve as biomarkers for the disease.

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Epizyme this week announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) — Epizyme today announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai and its diagnostics subsidiary Eidia said today that they are dissolving their diagnostics R&D subsidiary, Palma Bee'Z Research Institute, as part of the Eisai Group's transformation of its in vitro diagnostics development operations.

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

Pages

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.